APA (7th ed.) Citation

Zhang, L., Liu, Y., Yang, C., Ma, J., Li, Y., Luo, R., . . . Geng, C. (2025). Clinical efficacy and therapy response prediction of neoadjuvant dalpiciclib plus letrozole in postmenopausal patients with HR+/HER2- stage II-III breast cancer (DARLING 01). Breast Cancer Research, 27(1), 1-9. https://doi.org/10.1186/s13058-025-01976-0

Chicago Style (17th ed.) Citation

Zhang, Lina, et al. "Clinical Efficacy and Therapy Response Prediction of Neoadjuvant Dalpiciclib Plus Letrozole in Postmenopausal Patients with HR+/HER2- Stage II-III Breast Cancer (DARLING 01)." Breast Cancer Research 27, no. 1 (2025): 1-9. https://doi.org/10.1186/s13058-025-01976-0.

MLA (9th ed.) Citation

Zhang, Lina, et al. "Clinical Efficacy and Therapy Response Prediction of Neoadjuvant Dalpiciclib Plus Letrozole in Postmenopausal Patients with HR+/HER2- Stage II-III Breast Cancer (DARLING 01)." Breast Cancer Research, vol. 27, no. 1, 2025, pp. 1-9, https://doi.org/10.1186/s13058-025-01976-0.